103 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
9 May 24
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
7:36pm
of PWS.”
Financial Results
Soleno’s current research and development efforts are primarily focused on advancing its lead product candidate, DCCR … of $307.2 million.
Research and development expense was $14.6 million for the three months ended March 31, 2024, compared to $5.3 million in the same period
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
. is acting as the lead manager for the public offering.
Soleno intends to use the net proceeds from this offering to fund its current research … and development efforts primarily focused on advancing its lead candidate, DCCR tablets for the treatment of Prader-Willi Syndrome (PWS), and to provide
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
this offering to fund our current research and development efforts primarily focused on advancing our lead candidate, DCCR tablets for the treatment of PWS … the net proceeds from this offering to fund our current research and development efforts primarily focused on advancing our lead candidate, DCCR tablets
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
and estimated offering expenses payable by us.
We intend to use the net proceeds from this offering to fund our current research and development efforts … their option to purchase additional shares in full).
We intend to use the net proceeds from this offering to fund our current research and development
8-K
EX-99.1
oj8cg4iqln8bqidw0ky8
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
8-K
EX-10.1
nbdp2nkag35kq
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
gymarqoubtqdqgg89
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
rl1l2chb3s1iapdkg0
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
0rebdnre h4
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
m71uy9npsjwywj5oqvv
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
ufh39
9 May 23
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-10.1
1v1 4kmmf
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm